Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 4, 1998

View Archived Issues

Company Profile: Nortran

Dura: Q4 and FY 1997 highlights

Antifibrotic compounds discovered at Hoechst

TIMI 12 trial results published

Heterocyclic bradykinin antagonists from Hoechst

Hoechst reveals several series of Na+/H+ exchange inhibitors

Name change and relocation announced

Beneficial effects of vitamin C demonstrated in heart failure patients

Strategies for purging latently infected cells in HIV-positive patients studied at NIAID

NexMed completes phase I trial of ED product

Phase III trial compares immediate and delayed treatment with fomivirsen for CMV retinitis

New targets for stroke: neurotrophic growth factors

PRO-2000 gel well tolerated in phase I trial in healthy females

Preclinical studies support potential of CP-358774 as cancer treatment

StressGen licenses heat shock transcription factors

Neuroprotective effects of IL-1ra

Glaxo Wellcome characterizes in vitro/in vivo antibacterial activity of new trinem

Neuroprotective activity described for CoCensys neurosteroid

Pharmacia & Upjohn and Chiron establish HCV collaboration

Zeneca receives patent protection for new Diprivan formulation

New formulation of enalapril now available in U.K.

Promising preclinical results reported for Resolve

Potent SK(Ca) channel blocker prepared by European university researchers

Asacard approved in U.K.

Continued HIV suppression requires triple drug maintenance therapy

AVI BioPharma on the way to finalizing ImmunoTherapy acquisition

Abgenix and Schering-Plough collaborate on XenoMouse antibodies

FDA issues approvable letter for BioLon

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
Deals and an M&A strengthen end-of-year numbers
BioWorld
Two large deals and an acquisition, totaling about $4.64 billion in all, are helping wrap up what’s turning out to be a strong year. Through the first 11 months...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
Radiopharm Theranostics’ RAD-101 meets brain metastases endpoints
BioWorld
Radiopharm Theranostics Ltd.’s radiotracer RAD-101 met the primary endpoint in 92% of patients in the phase IIb imaging trial in brain metastases, according to...